Sites that come with the patients already in them
Traditional sites recruit strangers with ad budgets. Stryde sites are built inside specialty practices, so the eligible patients are already in the EMR, already seeing the PI, already showing up. That is why startup and enrollment run faster here, and why we publish the numbers.
Request feasibilityWhat do you get that a site list can't show?
- Embedded medical monitor. Our co-founder and CMO, Dr. Dipali Patel, is an experienced medical monitor working inside the network. Safety and eligibility questions get physician-level answers in hours, not escalation chains.
- Diversity by design, not by campaign. Our practices serve the communities they sit in, across DFW, Houston, Louisiana, and NJ/NY, so representative enrollment is a structural property of the model. Network aggregates are published on the performance board.
- Cell and gene ready. NIH IBC-RMS approval in place for advanced therapy trials.
- One contract, many sites. A multi-geography investigator network under a single operational and quality system, with central regulatory, quality, and finance teams.
How do you build enrollment numbers?
Bottom-up, never from prevalence. Active patient counts from practice EMRs, protocol filters applied in sequence, realistic screen-failure rates by study type, and coordinator capacity applied as a hard ceiling. The result is a number we would actually commit to. The full method, with a worked example, is on how we build an enrollment number.
When should a sponsor choose a community site over an academic site?
| Stryde embedded sites | Academic medical centers | |
|---|---|---|
| Best for | Outpatient enrollment at the treatment-decision moment; diversity targets; rescue timelines | Complex inpatient protocols; first-in-human units; KOL-anchored science |
| Patient source | The practice's own panel, already in the EMR | Referrals, often after key treatment decisions were made elsewhere |
| Startup | 6.5-week network median; as fast as two weeks when sponsor needs and documents allow | Published medians of 69 days (university) to 167 days (cancer centers) |
| Retention driver | Existing physician relationship; visits at the patient's usual clinic | Study-built relationship |
Benchmark sources on the performance board. The longer argument is in community sites vs academic centers.
Where are you a strong fit, and where aren't you?
Strong fit
- Outpatient Phase 2-4 in dermatology, rheumatology, and our active specialties
- Protocols with FDA diversity action plan targets
- Studies needing rescue sites with pre-tagged eligible patients
- Biologic and injectable protocols (infusion capability, cold chain in place)
- Rare disease work where community specialists hold the panel
Likely a better fit elsewhere
- Complex inpatient or confinement protocols
- First-in-human studies needing dedicated Phase 1 units
- Intensive serial PK sampling designs
- Indications requiring infrastructure our practices do not offer; an academic site may serve you better, and we will say so in the feasibility response
Therapeutic coverage
Send us your protocol synopsis. Preliminary feasibility in 48 business hours, or we tell you why not within 4.
Plenty of networks claim fast feasibility. Ours is a guarantee, with a published and tracked response-time median on our performance board, and an honest no within 4 hours when a protocol needs longer. Preliminary means PI interest, estimated eligible population from real network data, a realistic enrollment range, and capability fit. The full response with EMR queries follows.
Frequently Asked Questions (FAQs)
What is Stryde Research?
Stryde Research is a physician-owned Site Management Organization (SMO+) that runs clinical trials inside specialty physician practices. The network spans 20+ embedded research sites across Texas, Louisiana, New Jersey, and New York, with access to 1.5M+ patients across 100+ specialty clinics.
How is an embedded site different from a dedicated research facility?
A dedicated facility recruits unfamiliar patients through advertising. An embedded site places research staff inside an existing specialty practice, so eligible patients are already in the EMR and already trust the investigator. The result is faster startup, faster enrollment, and better retention.
How fast can Stryde respond to a feasibility request?
Preliminary feasibility in 48 business hours, or an honest answer within 4 hours explaining why a protocol needs longer. Preliminary includes PI interest, an estimated eligible population from network data, a realistic enrollment range, and capability fit.
Can Stryde run cell and gene therapy trials?
Yes. The network holds NIH IBC-RMS approval for advanced therapy trials, alongside experience across dermatology, rheumatology, neurology, pulmonology, and additional specialties.
How does Stryde achieve diverse enrollment?
By geography rather than campaigns. Our sites sit inside community practices serving South Asian, Black, Hispanic, and immigrant communities across our markets, so representative enrollment is a structural feature of the model, not an advertising outcome.
Want outcomes, not claims? See network results. Before the pitch, see our live performance metrics, enrollment results from real studies, or the way we build enrollment numbers.